Analgesic effect and side effects of celecoxib and meloxicam in canine hip osteoarthritis


Víctor Molina D
David Álzate V
Jhon Ruíz B
Manuela Urrea A
Juan Tobón J


Objective. To evaluate the pharmacological, clinical and toxicological effects of celecoxib and meloxicam for analgesia for 30 days in dogs with hip osteoarthritis. Materials and methods. Twenty-four patients were evaluated, 75% were females with an average age of 7.16 ± 2.06 years and twenty five percent were males with an average age of 7.83 ± 2.22 years. All patients had hip osteoarthritis and they were randomized into two groups; one group received oral celecoxib 5 mg/kg every 12 hours during one month and the second group received oral meloxicam 0.2 mg/kg every 24 hours during 1 month. The patients were evaluated for analgesia, and hematological, renal, liver, and coagulation tests on days 0, 10th and 30th after treatment initiation, and a gastric endoscopy on day 30. Statistical analysis was performed using a HSD Tukey test and c2 with a 5% level of statistical significance. Results. Both drugs reduced articular pain according to the Melbourne scale during the 30 days of treatment (p≤0.05). Hematological, renal, hepatic and coagulation tests were normal in both treatment groups. All patients presented chronic gastritis on endoscopy on day 30th. Conclusions. Both drugs decreased pain at day 30th without causing alterations in hematological, renal, hepatic or coagulation tests after 30 days of treatment. However, both drugs induced chronic gastritis.

Palabras clave


Los datos de descargas todavía no están disponibles.


Referencias / Ver

Sanderson RO, Beata C, Flipo R-M, Genevois J-P, Macias C, Tacke S, et al. Systematic review of the management of canine osteoarthritis. Vet Rec. 2009;164:418–24.

Innes FJ, Cayton J, Lascelles BDX. Review of the safety and efficacy of long-term NSAID use in the treatment of canine osteoarthritis. Vet Rec. 2010 Feb 20;166(1):226–30.

Lizarraga Madrigal I, Sumano Lopez H, Castillo Alcala F. Cyclooxygenase-2 selective inhibitors: Potential usage in dogs. Vet Mex. 2002;33(3):2–24.

Johnston S, M.McLaughlin R, Budsberg SC. Nonsurgical Management of Osteoar thritis in Dogs. Vet Clin Small Anim. 2008;38:1449–70.

Aragon CL, Hofmeister EH, Budsberg S. Systematic review of clinical trials of treatments for osteoarthritis in dogs. JAVMA. 2007;230(4):514–21.

Henderson AK, Webster CLR. Disruption of the Gastric Mucosal Barrier in Dogs [Internet]. 2006. Available from:

Nakagawa K, Yamagami T, Takemura N. Hepatocellular toxicosis associated white the alternate administration of carprofen and meloxicam in a siberian husky. 2005;67(10):1051–3.

Batlouni M. Antiinflamatorios No Esteroides: Efectos Cardiovasculares, Cerebrovasculares y Renales. Arq Bras Cardiol. 2010; 94(4):538-46.

Autefage A, Palissier FM, Asimus E, Pepin-Richard C. Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis. Vet Rec. 2011;168:617–23.

Bergh MS, Budsberg S. The coxib NSAIDs: potential clinical and phamacologic importance in veterinary medicine. J Vet Intern Med. 2005;19(1):633–43.

Choitsu SC, Soen S. Efficacy and Safety of the Selective Cyclooxygenase-2 Inhibitor Celecoxib in the Treatment of Rheumatoid Arthritis and Osteoarthritis in Japan. Digestion. 2011;83(1):108–23.

Anderson A. Treatment of hip dysplasia. J Small Anim Pract. 2011;52:182–9.

Michelin A de F, Ferreira Peres AA, Bitar Galvini B, Lopez Cruz L. Toxicidade renal de inhibidores selectivos da cicloxigenasa 2 : celecoxib e rofecoxib. Rev Ciênc Méd Campinas. 2006;4(15):322–32.

Vásquez-Cotés S, Vásquez-Fuertes L, Rodríguez-Alvárez M, Reig-Rincón de Arellano I, Martínez-Cócera C. Tolerancia a celecoxib y meloxicam en pacientes con intolerancia a analgésicos no esteroides. Med Interna. 2008;25(4):163–7.

Luna S, Bastilio A, Steagall P. Evaluation of adverse effects of long-term oral administration of carprofen, etodolac, flunixin meglumine, ketoprofen and meloxicam in dogs. Am J Vet Res. 2007;68:258–64.

Doig PA, Purbrick KA, Hare JE, McKeown DB. Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis. Can Vet J. 2000;41(1):296–300.

Tabibian J, Tabibian N, Kaufman D. Late-onset celecoxib induced combined hepato nephrotoxicity. Br J Clin Pharmacol. 2008;66(1):150–2.

Joubert KE. The effects of firocoxib (previcox) in geriatric dogs over a period of 90 days. JSAfr.vetASS. 2009;60(3):179–84.

Roberts ES, Van Lare KA, Marable BR, Salminen WF. Safety and tolerability of 3 week and 6 moths dosing of Deracoxib (Deramaxx) chewable tablets in dogs. Jvet Paharmacol Ther. 2008;32(329):337.

Agustí A, Danés I. Modificación del efecto antiagregante de ácido acetil salicílico por los fármacos antiinflamatorios no esteroideos. Med Clin Barc. 2004;123(11):433–4.

Goodman L, Gilman A, Hardman J, Limbird LE. Goodman & Gilman’s The Pharmacological basis of therapeutics. 12th ed. New York: McGraw Hill; 2006.

Lanas Arbeloa Á. Avances en patología gastrointestinal relacionada con el tratamiento con antiinfl amatorios no esteroideos y antiagregantes plaquetarios. Gastroenterol Hepatol. 2011;34(1):35–42.

Firth AM, Haldane SL. Development of a scale to evaluate postoperative pain in dogs. JAVMA. 1999;214(5):651–9.

Gómez LF, Hernánndez CA, Restrepo-Betancurt LF, Orozco S. Comparación de etomidato, ketamina y propofol como inductores para gastroduodenoscopia en perros. Rev Colomb Cienc Pecu. 2007;20(1):59–66.

Oddone AJ, Rodríguez-Jurado PM. Enfermedades Congénictas y Hereditarias de las Razas Caninas y Felinas. Primera. Buenos Aires: Intermedica; 2010. 147 p.

Hou Y, Wang Y, Lust G, Zhu L, Zhang Z, Todhunter RJ. Retrospective Analysis for Genetic Improvement of Hip Joints of Cohort Labrador Retrievers in the United States: 1970–2007. PLoS ONE. 2010;5(2):9410.

Che Y-F, Jobanputra P, Barton P, Bryan, S, Harris, G, Taylor, RS, et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008;12(1):25–32.

Llau JV, De Andrés, J J, Gomar C, Gómez-Luque A, Hidalgo F, Sahagún J, et al. Fármacos que alteran la hemostasia y técnicas regionales anestésicas y analgésicas: recomendaciones de seguridad (foro de consenso). R E V Soc Esp Dolor. 2001;8(1):337–48.

Campora C, Freeman KP, Lewis FI, Gibson G, Sacchini F, Sanchez-Vazquez MJ. Determination of haematological reference intervals in healthy adult greyhounds. JSAP. 2011 Jun;52(1):301–9.

Steagall, P, Mantovani FB, Ferreira TH, Salcedo E, Mouthi-o FQ, Luna LS. Evaluation of the adverse effects of oral firocoxib in healthy dogs. J Vet Pharmacol Ther. 2007; 30:2218–23.

Chopra S, Kishore-Saini R, Nath-Sanyal S. Intestinal toxicity of non-steroideal anti-inflammatory drugs with differential cyclooxigenase inhibition selectivity. Nutr Hosp. 2007;22(5):528–37.

Citado por